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Abstract 
Cytomegaloviruses (CMVs) are highly prevalent, persistent human pathogens that not only 
evade but also shape our immune responses. Natural killer (NK) cells play an important role 
in the control of CMV and CMVs have in turn developed a plethora of immunoevasion 
mechanisms targeting NK cells. This complex interplay can leave a long-lasting imprint on 
the immune system in general and affect responses towards other pathogens and vaccines. 
This review aims to provide an overview of NK cell biology and development, the 
manipulation of NK cells by CMVs and the potential impact of these evasion strategies on 
responses to vaccination. 
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Natural killer cells are lymphocytes that respond to various pathogens and tumors.  
Cytomegaloviruses have developed numerous immune-evasion mechanisms to compromise NK cell 
function. Following infection with cytomegalovirus, certain NK cell sub-populations expand and 
differentiate, leading to long-term changes in NK cell population and altered responses to other 
infections and vaccination.   
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Introduction 
Cytomegaloviruses (CMVs) are beta-herpesviruses that establish life-long persistent infection 
of their hosts. After resolution of acute infection, the virus enters a state of latency during 
which very few genes are transcribed and no new viral progeny are being generated. Latency 
is interrupted by occasional reactivations of the virus and expression of genes associated with 
the lytic virus life-cycle [1]. The success of CMVs as pathogens is a consequence of multiple 
immunoevasion mechanisms such as downregulation of immunoreceptor ligands or 
expression of decoy molecules that they employ against every arm of the immune system, 
including NK cells, which play an important role in the early control of virally infected and 
malignant cells [2]. Individuals lacking NK cells may suffer from recurrent virus infections, 
most commonly caused by herpes viruses and papilloma viruses, as well as increased 
susceptibility to malignant tumors [3-5]. However, in other cases, there is no obvious clinical 
immunodeficiency associated with the absence of NK cells, indicating redundancy with other 
immune compartments for distinct genetic deficiencies [6, 7]. As NK cells also regulate other 
arms of the immune response, their modulation by CMV can have broader consequences for 
immunity [8]. For instance, the strength of the primary NK cell response against the virus can 
have a significant impact on the adaptive immune response, although the underlying 
mechanisms for this are not yet clear and vary according to host and virus genotypes [9, 10]. 
CMV infection is associated with expansion of effector memory CD8 T cell clones that are 
sustained for the lifetime of the host and  can comprise a significant percentage of the total 
CD8 T cell population in aging individuals [11]. Multiple lines of evidence in experimental 
animals and in humans which will be discussed in this review, now indicate that CMV 
infection leaves a similar long-lasting imprint on NK cell phenotype and function, affecting 
NK cell responses to other pathogens and to vaccination.  
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Vaccines facilitate control and eradication of infectious diseases that have plagued humanity 
for centuries but new infections, including those with pandemic potential continue to emerge. 
Understanding the different factors that can influence the response to vaccination is crucial 
for developing effective vaccines against these new threats. Recent evidence suggests that 
NK cells can contribute to both the induction and the effector phases of vaccination-induced 
immunity but that this is dependent upon the CMV-infection status of the vaccinated 
individual. Here we provide an overview of NK cell biology and development, the 
manipulation of NK cells by CMVs and the potential impact of CMV evasion strategies on 
responses to vaccination. 
 
NK cell activity depends on a balance of signals from inhibitory and activating receptors 
As first-responders among lymphocytes, NK cells must be able to react quickly to a wide 
variety of stimuli. They do not possess a single specific antigen receptor but, rather, they 
express multiple receptors and co-receptors that, synergistically, allow them to recognize 
potential threats and coordinate responses with other immune cells. Whether an NK cell will 
attack or tolerate a tumor cell or an infected target cell depends on the net balance of signals 
transduced by this plethora of receptors. If activating signals prevail, NK cell can kill the 
offending cell by lysis or induction of apoptosis and/or can secrete cytokines and chemokines 
to activate other arms of the immune system [12]. 
All NK cell receptors are germline-encoded and are often present as co-receptors on other 
immune cells. Some of these receptors, as well as their ligands, are stochastically expressed 
which results in heterogeneity in the number and type of receptors expressed by each NK cell 
within an individual. For example, it has recently been estimated that individual humans may 
possess between 6,000 and 35,000 phenotypically distinct NK cell subsets [13]. Moreover, in 
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some cases both receptors and their ligands are encoded by polygenic loci with a high degree 
of polymorphism in the population that leads to differences in susceptibility of hosts to 
infection [14].  
Inhibitory NK cell receptors recognize self-molecules that are expressed on healthy cells and 
as such are responsible for the prevention of autoimmune responses, especially in the context 
of inflammation. These receptors also play a role in NK cell education and threshold-setting 
for future activation (reviewed in [15]). Downregulation of self-molecules can result in 
absence of inhibitory signals and may lead to “missing-self” recognition [16]. MHC Class I 
molecules (HLA Class I in humans) are the principal family of self-molecules recognised by 
inhibitory and activating NK cell receptors [16-18].  
In humans, there are three different families of NK cell receptors for MHC I:  Leukocyte Ig-
like Receptor (LIR-1), CD94/NKG2 receptors and Killer-cell Immunoglobulin-like Receptors 
(KIRs).  LIR-1 is an inhibitory receptor and recognizes all major groups of MHC Class I, 
although with varying specificities. CD94/NKG2 receptors can be activating (e.g. 
CD94/NKG2C) or inhibitory (e.g. NKG2A) but recognize only HLA-E, whereas, activating 
(short-tailed) and inhibitory (long-tailed) KIRs  recognize all classical Class I HLA molecules 
(A, B and C) but in an allele-specific, and in some cases, peptide-selective manner (reviewed 
in [19]). In addition, there are numerous non-MHC Class I ligands for NK cells including the 
Clr/Ocil ligands that are recognized by inhibitory NKR-PI C-type lectin receptors [20], 
nectins and nectin-like molecules that are recognized by the activating receptor DNAM-1, 
inhibitory TIGIT and CD96 that has so far been reported to display both inhibitory (in mouse 
models) and activating properties[21-24]. Finally, ligands for activating NK cell receptors 
can include self and altered-self molecules (including MHC-bound peptides); induced self-
ligands; foreign, virally encoded molecules; and immune complexes (immunoglobulin Fc 
binding to CD16) (reviewed in [15, 25]). Whilst such a wide arsenal of inhibitory and 
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activating NK cell receptors might seem redundant, evolution of diverse receptor-mediated 
pathways is likely to have been driven by pathogens, including cytomegaloviruses, which 
have developed mechanisms to interfere with nearly all of these pathways.  
Cytomegalovirus-encoded immunoevasins drive host evolution  
Cytomegalovirus (CMV) immune evasion strategies target multiple mechanisms in every arm 
of the immune response, permitting successful dissemination through the population and 
establishment of life-long, persistent infection. Human cytomegalovirus (HCMV) infects a 
major portion of the world‟s population [26] however due to strict species specificity it 
cannot be used to infect experimental animals. A number of closely related animal CMVs 
exist that are used as models; the best established and most widely used is murine CMV 
(MCMV) [27] due to the availability of numerous mutant mouse and virus strains. Rhesus 
CMV is highly related to HCMV and shares many gene families, however it is highly 
prevalent in both wild and captive rhesus monkeys making it difficult and expensive to 
maintain seronegative animals. Additionally, rhesus monkeys are much more expensive than 
mice and there are significantly fewer monkey strains available [28]. Finally, CMVs on their 
own represent excellent model organisms and tools for manipulating the immune system due 
to the features discussed below.  
CMVs modulate NK cell responses by engaging inhibitory and avoiding activating receptors 
using multiple and often polyfunctional immunoevasins with wide specificities for numerous, 
often unrelated, targets. Decoy molecules encoded by CMVs preserve cell surface expression 
of inhibitory ligands whilst engagement of activating receptors is avoided by downregulation 
of their ligands. Additionally, CMVs encode Fc receptors that interfere with NK-mediated 
antibody-dependent cell-mediated cytotoxicity(ADCC) and complement attack [29]. The 
plethora of HCMV and MCMV NK evasins is summarized in Table 1; details and 
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mechanisms of their action are beyond the scope of this review but can be found elsewhere 
[9, 29-33].  
One of the best-described CMV decoy molecules is the MCMV-encoded MHC I-like 
molecule, m157. Depending on the virus and mouse strain, m157 can engage inhibitory 
Ly49I and C receptors [34-36] and the activating Ly49H receptor [37, 38]. It has been 
proposed that inhibitory Ly49 and KIR receptors predate activating counterparts [39] so it is 
possible that m157 evolved originally as an inhibitory Ly49 receptor decoy but virus-
associated mortality subsequently drove evolution of the activating Ly49H receptor 
(reviewed in [31]). However, m157 has only a modest effect on NK cell function in vivo and 
only in C57BL/6-related mouse strains and it has recently been reported that wild mouse 
populations lacking Ly49H thrive despite the high prevalence of MCMV infection in the wild 
[40]. Inhibitory Ly49C is usually engaged in cis interactions with MHC I on NK cells. In cis 
interactions the receptor is interacting with its ligand present on the same cell and not on the 
target cell (trans interaction). If a receptor is engaged in cis it is not available for exploitation 
by m157 expressed in trans. It appears that viral evasion has “selected” inhibitory receptors 
that can ensure proper NK cell education and functionality in the presence of decoys by 
engaging in cis [35, 36, 41](for review on cis and trans interactions of cell surface receptors 
see [42]). Similarly, the HCMV-encoded decoy molecule UL18 engages the inhibitory 
receptor LIR-1 but the availability of LIR-1 is regulated by its cis interactions with  HLA 
molecules [43].  
MHC I molecules are very efficiently downregulated during both HCMV and MCMV 
infection in an effort to avoid presentation of virally encoded peptides to CD8 T cells. As 
MHC Class I  downregulation could lead to “missing-self” recognition and NK cell-mediated 
killing of infected cells, CMVs have developed strategies to either selectively downregulate 
MHC I molecules that are efficient presenters of peptide to CD8 T cells, while sparing those 
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that are better at engaging inhibitory NK cell receptors (HCMV) [32], or return some MHC I 
to the cell surface (MCMV) [30]. Moreover, HCMV stabilizes the expression of HLA-E, a 
ligand for the inhibitory CD94/NKG2A receptor, by providing a mimetic-peptide that 
overcomes inhibition of peptide loading [32, 44]. However, HLA-E in HCMV infected 
individuals is also recognized by the activating receptor CD94/NKG2C, although the 
specificity is much lower and co-engagement of NKG2A and NKG2C still results in 
inhibition of NK cell [45]. Nevertheless, the evolutionary pressure exerted by this recognition 
is sufficient to select for HCMV strains with polymorphisms that abrogate recognition by 
NKG2C but not NKG2A [46], at least in transplant patients. The impact of these 
polymorphisms on the expansion of CD94/NKG2C
+
 NK cells during HCMV infection is not 
yet known. 
Missing self-recognition can also be mediated by non-MHC I molecules; one such example is 
the MCMV-encoded decoy m12 that targets the inhibitory NKR-P1B receptor [47-49], and is 
assumed to have driven the evolution of the related activating receptor, NKR-P1C (NK1.1), 
that also recognizes m12 in a mouse- and virus strain-dependent manner [50]. The SLAM 
family of receptors (SFR) have also been shown to aid in MHC-I-dependent missing-self 
recognition [51]. The ongoing evolutionary arms race between viral immunoevasins and host 
defenses is also evident in the evasion of activating receptor NKG2D, with CMVs encoding 
multiple strategies to prevent surface expression of NKG2D ligands (Table 1). Finally, in 
silico models show that CMV-like viruses that modulate NK cell ligands and downregulate 
MHC I, can select for genetically diverse and highly allele-specific receptor families with 
activating and inhibitory members, such as KIR and Ly49 [52-55]. 
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Influence of CMV on NK cell education 
Binding of self-molecules via inhibitory receptors is also required for NK cell education and 
modulation of effector function. Since NK cell inhibitory receptors and their ligands are 
encoded by distinct loci located on different chromosomes, it is possible for some NK cells to 
express inhibitory NK cell receptors for which there is no self-ligand. Potential autoreactivity 
of such cells is prevented by a mechanism termed “licensing” or “disarming”: if an NK cell 
does not encounter a ligand for at least one inhibitory receptor during its maturation it 
becomes hyporesponsive towards targets with low or no MHC I (reviewed in [56]). In mouse 
models, NK cell responsiveness increases with each inhibitory receptor that can find its 
ligand during maturation [12, 57]. The tuning of NK cell responsiveness is not restricted only 
to the maturation stages, rather it‟s a continuous process depending on the availability of 
receptor ligands. Unlicensed cells are not redundant; the inflammatory environment can 
ameliorate their anergy and they can be effective against targets that express self-MHC I that 
would inhibit licensed cells, such as MHC I-expressing tumors or viruses such as CMV that 
encode NK cell inhibitory receptor decoys (reviewed in [12, 57]). Conversely, NK cells in 
mice that overexpress or constitutively express ligands for NKG2D or Ly49H receptor 
displayed tolerance against targets expressing these ligands (reviewed in [12, 58]).  
NK cell education can also be mediated by non-MHC I self-molecules [59]. For example, the 
SFR that have been shown to act as both inhibitory and activating receptors depending on 
adaptor molecules [60], can play a significant role in tuning of NK cell responsiveness 
although it is not yet clear whether this tuning is a consequence of their activating or 
inhibitory role [61, 62]. MCMV and HCMV regulate the expression of one SFR, 2B4 (Table 
1) [63, 64]. It is not known whether other SFRs are targeted by CMVs however, a recent 
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work demonstrated in mice that SFRs and their adaptor molecules are promising modulators 
that can enhance immune responses to vaccines [65].   
Although expression of NK cell receptors is often described as stochastic, a growing body of 
research reveals the impact of inhibitory receptor signaling during NK cell maturation on the 
expression of other NK cell receptors (reviewed in [12]). For example, signaling from 
activating NK cell receptors via SLP-76 changes the expression of inhibitory Ly49A, 
Ly49G2 and Ly49I receptors in mice  and completely abolishes acquisition of KIR2DL1, 
KIR2DL2/DL3, and KIR3DL1 in human NK cells and it has been proposed that this is driven 
by the expression of activating ligands on bone marrow stromal cells [66].  Interestingly, 
cytomegaloviruses have a wide cell and tissue tropism including bone marrow stromal cells, a 
tissue that is important for generation and maintenance of NK cells, and, in an influenza 
model, the bone marrow was found to be an important site of proliferation of long-lived 
memory-like NK cells [67]. It will be interesting to see whether bone marrow stroma 
influences the generation of CMV-induced memory-like NK cells and whether latent CMV in 
the bone marrow modulates NK cell maturation and education. 
Long-term impact of MCMV on NK cell phenotype, behavior and responses to other 
pathogens  
Following infection or vaccination, pathogen-specific cells of the adaptive immune response 
undergo clonal expansion (proliferation) and differentiation followed by contraction of the 
effector cell pool and formation of long-lived, highly antigen-specific memory cells with the 
ability to mount fast and efficient recall responses. While most NK cell receptors are not 
antigen specific, in certain mouse strains the activating Ly49H receptor specifically 
recognizes MCMV m157, as described above  ([37, 38] and reviewed in [68]).  However, this 
pathogen-specific recognition is restricted only to C57BL/6 and related mice and a few 
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laboratory strains of MCMV (e.g. most commonly used Smith and K181 strains) [33, 36, 69-
72]. Furthermore, serial passage of WT MCMV in Ly49H
+
 mice results in the accumulation 
of mutations that abrogate interaction between MCMV and Ly49H [69, 73], while in mixed 
infections (infection with 2 or more strains of MCMV)  only MCMV strains that do not 
engage Ly49H are able to reach the salivary gland, the main dissemination place [74].  
Nonetheless, Ly49H and m157 interaction results in the antigen-specific expansion of 
Ly49H
+
 cells, control of the virus and generation of long-lived memory-like NK cells with 
capabilities similar to memory T cells (Error! Reference source not found.A) and is currently a 
major model for studying virus-induced memory NK cell formation. MCMV-induced 
memory-like NK cells are less reliant on STAT1- and STAT4-mediated signals and produce 
less IFN- in response to IL-12 with IL-18 compared to naïve or Ly49H- NK cells [75]. These 
cells also display inappropriate NK cell homing to infected tissues following adoptive 
transfer  and reduced IFN- production during subsequent influenza or listeria infections, 
whilst still generating appropriate responses to MCMV m157
+
 [75]. It appears, therefore, that 
expansion of CMV-specific memory-like NK cells could compromise responses to other 
infections, however this may be offset by increased responsiveness to antibody-mediated 
signals (ADCC) (see below). 
HCMV infection leads to accumulation of terminally differentiated NK cells with potential 
long-term consequences 
Human CMV infection is characterized by accumulation of highly differentiated subsets of 
NK cells (Error! Reference source not found.B).  Over ten years ago, Guma et al. observed an 
expansion of mature (CD56
dim
CD16
-
) NK cells expressing CD94/NKG2C
+
 in HCMV
+
 
individuals [76]. This observation has now been corroborated in HCMV-infected children 
[77], in adults undergoing acute HCMV infection [78] and in hematopoietic stem cell 
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transplant patients with reactivated HCMV [79, 80], among whom HCMV reactivation is 
associated with significantly increased NK cell maturation rates [80-82]. As described above, 
CD94/NKG2C is an activating receptor for HLA-E, which is stabilized at the surface of 
HCMV-infected cells, suggesting that this is a host protective response to control HCMV 
infection and maintain latency. Moreover, many expanded, CD94/NKG2C
+
 cells 
subsequently lose expression of the FcRγ adaptor molecule [83, 84]. Despite the FcRγ loss, 
not only is signaling through the Fc-receptor CD16 preserved (due to the ability of CD16 to 
transmit signals through CD3ζ) but FcRγ- cells display enhanced ADCC responses to HSV-1 
[85] and influenza-infected targets [86], as well as against antibody-opsonized HCMV virions 
[87], especially if NKp46 [85] or CD2 are also engaged [88, 89].  HCMV-expanded NK cells 
are long-lived [90, 91] with stable epigenetic imprints that are transmitted to the cell progeny 
and that resemble those found in memory T cells [86, 92]. CD94/NKG2C
+
 FcRγ- NK cells 
are thus highly adapted to combat HCMV re-infection or reactivation in seropositive 
individuals, although CMV infection can also prompt the expansion of NKG2C
-
 NK cell 
population  (discussed below). 
Differences are emerging, however, in the phenotype of CMV-induced memory-like NK cells 
in humans and mice. Many NK cells in HCMV
+
 individuals are deficient in the transcription 
factor PLZF, and many of PLZF- cells also lack the SYK, EAT-2 and FcRγ adapter 
molecules (Figure 1B) as a consequence of hyper-methylation of their promoter regions. 
Furthermore, epigenetic modification (methylation) of the IFN-γ gene promoter explains 
increased secretion of this cytokine upon re-stimulation [93]. Interestingly, although NK cells 
in HCMV
+
 patients display demethylation of  PRDM1 and ZBTB32 genes [93] the same 
genes that regulate proliferative burst of Ly49H+ memory-like NK cells in mice [94], mouse 
memory-like NK cells are FcRγ and Syk sufficient [86]. Stable epigenetic relaxation of 
cytokine secretion and regulators of proliferation could be potentially dangerous, especially 
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in cells that are highly activated by an inflammatory milieu. In the case of human 
CD94/NKG2C
+
 NK cells, this danger is circumvented by downregulation of receptors for IL-
12 and IL-18 [95] common NK cell activating cytokines, and by dampening of tonic 
signaling from activating receptors mediated by Syk, EAT-2 and  FcRγ [96].  
Although HCMV-expanded NK cells display a mature phenotype associated with reduced 
cytokine responsiveness, IFN- cytokine-driven responses of NKG2C+CD57- NK cells in 
HCMV
+
 individuals are strongly boosted by vaccination compared to their CD57
bright
 
counterparts consistent with further differentiation steps occurring before these cells lose 
cytokine responsiveness [97]. The extent to which highly differentiated FcR-, PLZF- 
adaptive NK cells participate in vaccine-induced responses has not yet been fully addressed 
and it is conceivable that vaccines or adjuvants relying heavily on cytokine-driven pathways 
may be less potent in HCMV
+
 individuals with high frequencies of these cells. 
The molecular mechanisms behind expansion of the CD94/NKG2C
+
 subset of NK cells are 
not yet completely clear. Although CD94/NKG2C
+
 NK cells expand only in HCMV infected 
individuals (reviewed in [98]), the rate and extent of the expansion varies greatly among 
HCMV
+
 individuals (reviewed in [99]). CD94/NKG2C
+
 NK cells can expand in vitro when 
co-cultivated with fibroblasts undergoing productive HCMV replication. HLA Class I 
regulators encoded by the US2-11 gene region are required for this expansion but, despite the 
demonstration of weak interactions between NKG2C and UL18 [100, 101] neither UL16 nor 
UL18 are required. Interaction of NKG2C with HLA-E, and IL-12 secretion by monocytes, 
has also been identified as prerequisites for the expansion of NK cells in this context [102]. 
The proportion of CD94/NKG2C+ NK cells increases with age in different populations and 
surface levels of NKG2C correlate with the copy number of KLRC2, the gene encoding 
NKG2C [84, 103-105]. Among congenitally infected children, symptomatic HCMV infection 
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was associated with higher proportions of CD94/NKG2C
+
 NK cells [105], suggesting that 
their expansion is ligand-driven. Among African children, anti-HCMV antibody titres were 
higher in KLRC2
-
 heterozygous and homozygous null individuals than in homozygous 
KLRC2
+
 children suggesting that lack of KLRC2 impairs control of the virus [104], but this 
was not seen in adults in the same community or in congenitally infected children [105]. A 
recent finding showing earlier accumulation of effector memory CD45RA
+
 CD8 T cells in 
KLRC2
-/-
 individuals provides a possible explanation for this discrepancy [88].  
The CD94/NKG2C
+
 NK cell population is not the only NK cell population that proliferates in 
response to HCMV infection. CD57
hi
NKG2A
-
NKG2C
-
 expanded populations have been 
observed in both NKG2C sufficient and deficient subjects; a recent study identified 
expansion of FcRγ–LIR-1+ cells in both NKG2C+ and NKG2C- NK cell populations among 
CMV
+
 renal transplant patients, irrespective of their KLRC2 genotype, although the FcRγ–
LIR-1
+
 NKG2C
-
 cells displayed greater ADCC against anti-CMV antibody-coated targets 
than did the FcRγ–LIR-1+ NKG2C+ population [106]. A recent report analyzing expansion of 
NK cells against HCMV-infected targets in vitro demonstrated expansion of NK cells 
independently of NKG2C expression [107]. It is not yet clear what drives the expansion of 
these CD94/NKG2C- NK cells. Although it was originally associated with the presence of 
activating KIR receptors of KIR B haplotype [108, 109], a later study found no difference 
between overall frequencies of activating KIRs between NKG2C- and NKG2C
+
 memory-like 
NK cells [88]. Both NKG2C- and NKG2C
+
 memory-like NK cells showed enhanced ADCC 
responses, higher levels of DNAM-1 and CD2 and demethylation of the IFNG promoter but 
were poorly responsive to IL12/IL18 and expressed lower levels of NKp46 [88]. 
Cytokine-induced memory-like NK cells in CMV infection and vaccination 
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In addition to CMV-induced memory-like NK cells, cytokine-induced memory-like NK cells 
(CIML) have been reported in mice and in humans (reviewed in [110]). Pre-activation of 
mouse NK cells with a cocktail of  IL-12, IL-18 and low dose IL-15 gave rise to cells that 
secreted increased levels of IFN-γ following activation through activating receptor 
engagement or following cytokine-stimulation up to 3 weeks later [111]. The strength of the 
subsequent response depended on the duration of pre-activation and enhanced responsiveness 
was maintained after homeostatic proliferation, indicating heritable epigenetic modification 
[112]. However, in contrast to virus-induced memory-like NK cells, CIML NK cells did not 
show enhanced cytotoxicity and enhanced cytokine production was lost by week 12. The 
upregulation of IL-2R (CD25) plays a key role in the maintenance of human CIMLs which 
mount strong secondary responses in presence of picomolar concentrations of IL-2 [113]. 
Murine CIML also rely on common-γ chain cytokine signaling for their long term 
maintenance [112].  Similar observations have been made for human NK cells pretreated in 
vitro with various combinations of IL-12, IL-15 and IL-18 [114] (Figure 2) and it is thus 
feasible that the inflammatory environment associated with acute viral infection, including 
CMV infection, may contribute to the formation of memory-like NK cells in vivo in humans 
and in mice. Indeed, induction of long-lived CIMLs in parallel with Ly49H
+
 memory-like 
NK cells has recently been reported in mice [115] and another study has shown that IL-12 
(but not Ly49H-m157) is required for induction of IL-2R during MCMV infection [116]. In 
the context of tumors, however, CIMLs are generated to a much lower extent and their 
responses - against the tumor itself or after engagement of NK1.1 or NKG2D ligands - are 
much weaker than those of MCMV-induced Ly49H
+
 memory-like NKs [115]. However, 
when transferred into the MCMV-free environment, CIMLs showed better survival and 
persistence than their virally induced counterparts.  
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This recent appreciation of the possibility of enhancing or modifying NK cell responsiveness 
by pre-activation with cytokines or exposure to viruses, opens up the potential for new 
prophylactic and therapeutic interventions (designed to generate memory-like NK cells) for 
combatting infection or malignancy (Figure 2). In humans, in vitro stimulation of peripheral 
blood mononuclear cells (PBMC) with vaccine antigens leads to the bystander activation of 
NK cells in individuals naturally exposed to, or previously vaccinated against, the 
corresponding pathogens (Figure 2,  [95, 117, 118]). Active vaccination (with rabies, malaria 
RTS,S, influenza TIV and LAIV, BCG and therapeutic HIV gp120 vaccines) has been shown 
to induce vaccine antigen-specific CD4
+
 T cell and IL-2 dependent NK cell responses to the 
vaccinating antigens (Table 2) [119-124]. As for CIMLs, cell surface expression of CD25, 
forming the high affinity interleukin-2 receptor (IL-2R) and thereby increasing sensitivity to 
antigen-induced IL-2, has been shown to be an important feature of vaccine-induced NK cell 
responses [119, 122, 123, 125, 126]. Whole organism vaccines including influenza, yellow 
fever, BCG and DTPiP (which encode pathogen associated molecular patterns, PAMPS) are 
potent inducers of myeloid cell-derived IL-12 and type I interferons which not only synergise 
with IL-2 to activate NK cells after vaccination [119, 122, 124] but also induce CIMLs [97, 
119, 124, 127]. In sharp contrast to CMV infection, however, vaccination and cytokine-
mediated pre-activation lead to a temporary expansion (or  redistribution) of less 
differentiated CD56
bright
 and CD57- CD56
dim
  NK cell subsets [97, 119, 124, 125, 127] but 
these eventually revert to pre-vaccination levels. For example, the elevated cytokine driven 
response observed after influenza or yellow fever 17D vaccination of Europeans persisted for 
up 3 months [104, 127], the response to influenza or DTPiP vaccination of Gambians lasted 
for up to 6 months and the response to BCG vaccination in South Africans lasted for up to 1 
year [97, 124]. 
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Broader effects of HCMV exposure on vaccination outcomes 
A broader influence of HCMV infection on vaccine induced immunity has been inferred from 
several studies comparing naturally occurring or vaccine-induced antibody levels or T cell 
responses against distinct pathogens in HCMV
+
 to HCMV- individuals. For anti-influenza 
responses, the impact of HCMV infection can be positive or negative depending on age and 
the immune readout. Poor overall health indicators have been associated with higher HCMV 
antibody titres, higher NK cell frequencies and lower B cell frequencies in the elderly [128] 
and inverse correlations have been reported between  anti-HCMV IgG titres and vaccination-
induced antibodies to influenza in the elderly [128] and in healthy young adults [129, 130]. 
Other studies have demonstrated either higher [131] or lower [132] antibody responses to 
influenza vaccination in HCMV- compared to HCMV
+
 young adults, suggesting that the 
duration of HCMV infection (acute versus longstanding) may affect the response to 
vaccination. In support of this hypothesis, young mice with recently established MCMV 
infection displayed better IFN-dependent control of influenza infection and increased 
frequencies of influenza antigen-specific CD8
+
 T cells compared to older mice with chronic, 
latent MCMV infection [132]. If confirmed in larger studies, CMV-induced enhancement of 
anti-viral immunity in the recently infected may confer a survival advantage in early or mid-
life but CMV-mediated immune senescence would reduce longevity in later life. This 
dynamic might therefore prove beneficial to children in many low-income countries with 
extremely high HCMV seroprevalence despite evidence of potentially deleterious effects in 
older populations in industrial nations [26, 104, 133-135]. 
The impact of HCMV infection on NK cell responses to vaccine antigens 
The impact of HCMV infection on vaccine antigen or cytokine-driven response pathways can 
be profound. In vitro NK cell IFN- responses to several previously encountered vaccine 
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antigens, including Influenza, whole cell pertussis and DTPiP (alone or co-stimulated with 
low concentrations of IL-12 and IL-18) are impaired in HCMV
+
 individuals [95, 97, 119]. 
This effect is consistent with the well-documented impairment of NK cell IFN- and CD25 
responses to exogenous cytokines among HCMV
+
 individuals [95, 118, 119, 136, 137],  and 
suggests that HCMV infection impairs the NK cell response to vaccine antigen-induced IL-2 
[95, 119]. As demonstrated for CIML, post-vaccination, NK cells appear to be reliant on 
cytokine-driven induction of CD25 for their maintenance and function, raising the possibility 
that production of, or responses to, the costimulatory cytokines (type I IFNs, IL-12 or IL-18) 
that are required for CD25 induction may be reduced in HCMV
+
 individuals [113, 119]. This 
is consistent with the impaired NK cell responses of HCMV
+
 individuals reflecting, in part, 
their low frequencies of less-differentiated CD56
bright 
and CD56
dim
CD57-  NK cells, which 
are intrinsically more cytokine responsive [95, 119]. However, chronic HCMV infection 
reduces the cytokine responsiveness of all NK cell subsets [95, 119], indicating that HCMV 
infection has much broader effects on NK cells, either by affecting their differentiation or 
licensing or by reducing the costimulatory capacity of accessory cells.   
Remarkably, although vaccination results in limited boosting of vaccine antigen driven 
responses, several vaccines boost the responses to higher concentrations of cytokines 
predominantly in HCMV
+
 individuals where these responses are down-regulated. Influenza 
vaccination preferentially boosts IL-12
 
and IL-18 stimulated NK cell IFN-, CD25 and 
CD107a expression in HCMV
+
 Europeans, while both TIV (Trivalent Influenza Vaccine) and 
DTPiP have this effect in African populations where HCMV infection is near universal [97, 
119]. The similar boosting of NK cell IFN- responses to cytokines after Yellow fever 
vaccination in Europeans or BCG vaccinated South African populations, although not 
explicitly investigated according to HCMV exposure, is also likely to involve HCMV
+
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subjects[124]. The boosting of cytokine-driven responses in all of these studies preferentially 
expands or activates less differentiated subpopulations of NK cells. 
 
Receptor-mediated activation and ADCC in the context of CMV infection and vaccination 
Whilst CMV infection negatively influences vaccine-driven responses that are reliant on 
accessory cytokines, NK cell activation via other pathways can also be adversely affected by 
CMV infection.  For example, murine Ly49H
+
 „memory-like‟ NK cells rely on co-stimulation 
via DNAM-1 and its induced ligands on macrophages and dendritic cells [138]; CMV-
mediated down regulation of these ligands may have consequences for responses to infection 
or vaccination. Similarly, in humans, reduced expression of NKp46, and reduced NKp46 
signalling capacity in adaptively expanded NK cells in HCMV+ individuals [92, 136, 137], 
could compromise responses to influenza virus by inhibiting the costimulatory interaction 
between NKp46 and viral haemaglutinin [139]. Moreover, US12-mediated down regulation 
of B7-H6 (a key ligand for NKp30) on HCMV-infected fibroblasts can lead to reduced NK 
cell degranulation [140]. However, CD94/NKG2C
+ 
NK cells show enhanced cytotoxic 
activity against a range of tumour cell lines which vary greatly in their expression of HLA-E, 
indicating that there may be conserved expression of receptors for other activating ligands 
[141]. Indeed, HCMV-expanded NK cells rely on signalling via accessory receptors 
including CD2 and its ligand, CD58, on accessory cells [88, 89]. On the other hand, HCMV-
expanded, “adaptive”, CD94/NKG2C+CD57+NK cells express high levels of CD16, signal 
very effectively via CD3ζ and possess epigenetic modifications leading to enhanced receptor-
mediated cytotoxicity and IFN- production [92, 93]. Together these modifications lead to 
greatly enhanced capacity for CD16-mediated ADCC, which may compensate for their loss 
of cytokine responsiveness [83, 86, 87, 92]. Interestingly, HCMV-expanded memory-like NK 
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cells do not appear to target autologous CD4+ T cells [96], a regulatory feature of NK cells 
described in murine models of virus-induced immune responses [142]. Such preservation of 
pathogen or vaccine-specific CD4+ T cells is likely to be important for the maintenance of 
both vaccine induced CIML and HCMV-associated, adaptive NK cell expansions. 
 
Concluding remarks: 
Although it is clear that cytomegaloviruses are major drivers of cellular immune 
differentiation, affecting NK cells as well as T cells, the full impact of CMV on infection, 
vaccination and healthy life span is still unclear. In the case of NK cells, the gradual 
differentiation away from cytokine-dependent signalling pathways towards antibody 
dependent or other receptor-mediated responses could be beneficial in the long-run, with 
cytokine-dependent activation on primary exposure to any given pathogen giving way to 
antibody-mediated activation during subsequent infections. The timing of HCMV infection, 
and the rate of subsequent cytokine-driven expansion of “adaptive” NK cells, together with 
host genetic background, will determine the relative costs and benefits of this process. Whilst 
CMV immune evasins may have evolved to promote persistence of virus in the host, further 
research is needed to establish which of the affected pathways are critical for immune 
defence against other pathogens. One as yet unconsidered aspect of this interaction between 
CMV and the cellular immune system is the potential use of CMVs as vaccine vectors [143-
149]. CMV can induce long-term expansion of antigen-specific CD8 T cell clones, which 
could be highly beneficial in a vaccine. Simultaneous deletion of the NK cell imunoevasins 
has proven to be a good strategy for virus attenuation without compromising CD8 T cell 
responses. The concurrent potential of CMV-vectored vaccines to mature NK cells towards 
potent antibody-dependent effector cells should however also be explored. 
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Table 1. Human and mouse CMVs‟ NK cell evasion strategies. (M) denotes MCMV‟s genes.  
 
Immunoevasin Target receptor Action References 
Regulators of MHC I expression 
UL40 
NKG2A, 
NKG2C, KIRs 
(?) 
Provides peptide for loading and 
stabilization of HLA-E and UL18 
[44, 150, 
151] 
m04 (M) 
inhibitory Ly49s 
and Ly49P (act) 
Escorts some MHC I to the cell 
surface, enhances interaction with 
inhibitory NK cell receptors 
[152-155] 
Virus encoded decoy molecules 
UL18 
LIR-1, unknown 
activating 
receptor 
Inhibition of LIR-1
+
 and activation of 
LIR- NK cells 
[156] 
m12 (M) 
activating and 
inhibitory NKR-
P1 
Activation or inhibition of NK cells, 
depending on the mouse and viral 
strain. 
[47, 50, 
157, 158] 
m144 (M) 
unknown 
inhibitory 
receptor 
Inhibits NK cell responses [159] 
m157 (M) 
Ly49H (act), 
Ly49C, Ly49I 
(inhib) 
Ligand for inhibitory Ly49I/C and 
activating Ly49H receptors. 
Activation of Ly49H
+
 cells in 
C57Bl/6 mouse strains. 
[37, 38] 
Prevention of activating receptor engagement 
US9 
NKG2D 
Proteasomal degradation of 
MICA*008 
[160] 
UL16 
intracellular retention of MICB, 
ULBP-1, ULBP-2 and ULBP-6. UL16 
with bound ligands is further targeted 
to lysosomal degradation by US20 
family members. 
[140, 161-
163] 
US18, US20* 
lysosomal degradation of full length 
MICA 
[164] 
US12, US13 proteasomal degradation of ULBP-2, [140] 
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* US2 and US12 family members have been shown to target multiple membrane proteins 
[140, 175] whose relevance to NK cell immune evasion is not yet clear. In addition, deletion 
of individual US12 family members resulted in changes in NK cell reactivity towards 
infected cells [175] however the receptors mediating this recognition not yet known. 
  
and US20 MICB and UL16 
miR-UL112 inhibition of MICB mRNA translation [165] 
UL142 
downregulation of full-length MICA 
and ULBP3 from the cell surface 
[166, 167] 
m138 (M) 
downregulation of surface MULT-1, 
H60a and RAE1-ε 
[168, 169] 
m145 (M) Intracellular retention of MULT-1 [170] 
m152 (M) 
retention of all Rae isoforms with 
varying efficacy, H60a and MHC I in 
the ER. 
[171, 172] 
m155 (M) intracellular retention of H60a 
[168, 169, 
173, 174] 
m154 (M) 2B4 
Lysosomal and proteasomal 
degradation of CD48 
[64] 
US2* DNAM-1, CD96 
degradation of Nectin-2 and 6 α-
integrins 
[175] 
UL141 DNAM-1, CD96 
Downmodulation of surface 
expression of PVR and Nectin2 
[175-177] 
m20.1 (M) DNAM-1 
Downmodulation of surface 
expression of PVR 
[178] 
US18, US20 NKp30 
inhibition of surface expression of 
B7-H6 
[140] 
pp65 NKp30 dissociation of ζ-chain from NKp30 [179] 
UL141 TRAIL 
retention of Trail-R1 and Trail-R2 in 
the ER 
[180, 181] 
m166 (M) TRAIL 
Surface expression inhibition of 
TRAILR 
[182] 
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Table 2: NK cell responses after active vaccination and accessory cytokine requirements 
 
Vaccine Composition/ 
Adjuvant 
NK cell response   Accessory 
cytokine 
requirement or 
association 
Reference 
BCG (Bacillus 
Calmette–Guérin) 
Attenuated 
whole organism 
IFN-γ IL-2, IL-12, IL-
18 
[124] 
BCG Attenuated 
whole organism 
IFN-γ (ex-vivo)  [183] 
HIV Therapeutic 
subunit 
gp120/nef/tat 
vaccine 
IFN-γ IL-2, IL-12 [123] 
Influenza  Intramuscular 
or Intradermal 
Trivalent 
inactivated 
(TIV) or Live 
attenuated 
(LAIV) 
IFN-γ, CD25, 
CD107a 
 
IL-2, IFN- 
 
 
 
[119] 
 
 
Influenza TIV or seasonal 
infection 
CD69, CD25 (ex-
vivo) 
 [122] 
Influenza TIV IFN-γ  [184] 
Influenza TIV IFN-γ, CD25, 
CD107a 
 [97] 
DTPiP 
(diphtheria, 
tetanus, pertussis, 
inactivated 
poliovirus) 
Subunit IFN-γ  [97] 
Malaria RTS,S Conjugate IFN-γ, CD69, 
 
IL-2 [121] 
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Rabies Inactivated 
whole organism 
IFN-γ, CD69 
CD107a, perforin 
IL-2, IL-12, IL-
18 
[120] 
Yellow Fever Live attenuated 
whole organism 
Ki67, CD69 IFN Type I/III [127] 
 
Figure legends 
Figure 1.  
CMV infection induces long-lived memory-like NK cells in mice and humans.  (A) 
Around half of all NK cells in C57BL/6 mice express Ly49H. Upon MCMV infection, they 
proliferate strongly and efficiently control the virus [184], even upon transfer into Ly49H- 
mouse strains [185]. Following viral clearance, the expanded pool of Ly49H+ cell contracts 
leaving a small proportion of long lived NK cells (detected up to 70 days PI) with recall 
ability reminiscent of memory T cells and with diminished ability to respond to other 
pathogens or MCMV lacking m157 [74]. Like T cells, memory-like NK cells require  pro-
apoptotic Bim-signaling for efficient contraction and memory formation [186], as well as co-
stimulation via other co-stimulatory receptors such as DNAM-1 and Ly49D [114, 187] (not 
shown).  
(B) In physiological conditions, two subsets of human NK cells exist. Functionally competent 
but immature CD56brightCD16- NK cells that mostly reside in secondary lymphoid organs, 
express inhibitory NKG2A, are excellent cytokine producers but poor killers give rise to the 
fully mature and cytotoxic, major NK cell population in the blood characterized as 
CD56dimCD16+NKG2A-/+ inhibitory KIR+ cells [188, 189]. Upon HCMV infection, a new 
subset appears among the fully mature CD56dimCD16+ population that is characterized by 
increased levels of NKG2C compared to NKG2C+ cells in HCMV- patients [77] (although 
not all expanded cells are NKG2C+), high levels of LIR-1 and, in many cases, CD57 (marker 
of fully mature cells) [77],  perforin  and granzyme expression, and the increased ability to 
secrete IFN-γ and TNFα. These cells often express at least one inhibitory self-binding KIR 
that allows licensing of these cells [80, 95, 107, 190]. Expanded NKG2C+ NK cells in 
HCMV+ TAP-deficient patients express polyclonal KIRs and are unresponsive towards HLA 
I negative targets [191].  Furthermore, most of these cells are deficient for adaptor molecule 
FcRγ and, consequently, express lower levels of those receptors that depend on FcRγ for 
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signal transmission such as NKp30 and NKp46 [82, 84, 86], while there are no changes in the 
expression of DNAM-1 and 2B4. Some also lose signaling molecules SYK and EAT-2 [92]. 
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Figure 2.  
 
Human cytokine-induced memory-like NK cells. Human NK cells can differentiate into 
CIMLs following in vitro treatment with cytokines or after vaccination. In vitro, both 
CD56bright and CD56dim cells can give rise to CIMLs. CD56bright CIMLs show a greater 
capacity to produce IFN-γ and fail to differentiate into CD56dimNK cells. Unlike virus-
induced memory-like NK cells, human CIMLs are characterized by lack of CD57 and 
increased surface expression of NKG2A, CD94, NKp46 and CD69, which correlate with 
their ability to secrete IFN-γ. CIMLs that develop after vaccination are similar to in vitro 
generated cells in terms of increased IFN-γ secretion, enrichment for  CD57- cells and 
induction of IL-2R [118, 121, 122, 124, 125]. 
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